26th September, 2018 On the eve of the UNHLMTB meeting, results from the Phase 2b M72/AS01E vaccine trial were published in the NEJM. This study represents the first TB vaccine that is able to provide 54% protection against pulmonary tuberculosis diseases in ...
September 2018
Is CD153 essential for M.tb control ?
25th September, 2018 CD4 T cells, particularly those that express IFN-γ have been shown to be essential for control of Mycobacterium tuberculosis infection in both animal models and humans. However, numerous studies have shown that IFN-γ expression by CD4 T cells...
Omentin-1 rescues inflammation-induced osteoporosis
19th September, 2018 Recent work by Shan-Shan Rao et. al, has highlighted the potential of Omentin-1 in downregulating the activity of proinflammatory cytokines, thereby unravelling its mechanism ...
New hope from chronic HBV patients: non-replicative Ad-HBV vaccine
14th September, 2018 Hepatitis B (HBV) remains a global health problem, with two billion people having serologic evidence of past or ongoing HBV infection.An estimated 257 million people, 3.5% of the global...
Have you heard of analytic treatment interruption of HIV ART?
12th September One of the goals for the HIV research field is to achieve a functional cure for HIV, the elimination of detectable virus without the use of ART. Clinical validation of new treatment options ...
A novel function of the antihelminthic drug Praziquantel: new strategy for combatting schistosomiasis
Interesting work by Chan and colleagues describes an unknown mechanism of action of the tetracyclic tetrahydroisoquinoline praziquantel (PZQ) the drug ...
What is the incubation period of TB?
5th September 2018 A recent Analysis by Behr et al., “Revisiting the timetable of tuberculosis”, highlights the need for improved understanding of the timeline of TB progression and its implications for TB elimination strategies. In this analysis article, Behr et al., discuss various longitudinal studies that illustrate that majority...